With the global sports nutrition market worth something in the vicinity of €15 billion and personalized nutrition around €2-3bn, according to market analysts – the cross-over of personalized sports nutrition in 2021 is relatively niche.
Philipp Merk, co-founder and managing director at German personalized nutrition firm Loewi, says sports nutrition accounts for the biggest slice of his firm’s business – about 40% (immunity being the next biggest chunk).
Loewi was founded in early 2019 as a spin-off from a Technical University of Munich, Olympic athlete-focused personalized nutrition project. Its model feeds blood sample biomarker data and questionnaire responses through algorithms to make its mostly food supplement (but also food recommendations) that typically cost users about €75 a month.
“We have basically combined this super-laborious method with my background in data science and artificial intelligence to make it scalable,” Merk says. “So we have a blood test you do at home independent of a doctor and a database of over 15,000 medical studies.”
“We have thousands of interactions between nutrients, diseases, medications, allergies – really everything that is known – and this is also how we can make sure we are never harming any of our customers.”
Merk says Loewi’s ever-growing data set was driving evermore refined recommendations.
“We have algorithms calculating the individual dose for each nutrient and with each blood test that we conduct we use machine learning to build a mathematical model of their metabolism. We basically have a curve where we know which dosage we need to achieve which blood value. The cool thing is with each customer that comes through the system our model gets better and better. It’s like self-improving machinery.”
The first-ever pan-European good manufacturing practice (GMP) for sports nutrition is the topic of hot debate as industry weighs up whether it will help enforce quality and weed out bad actors lacing products with doping analogs like steroids and stimulants.
Specialized Nutrition Europe (SNE) and The European Federation of Associations of Health Product Manufacturers (EHPM) argue the voluntary GMP will build confidence in the sector among elite and other athletes.
However, the European Specialized Sports Nutrition Alliance (ESSNA), Europe’s largest sports nutrition-focused industry body, says the standard is ill-defined and will sow confusion.
Deep data dive report examines factors and trends driving the infant and pregnant/breastfeeding women’s probiotics category and scrutinises increasingly online-engaged consumers and their often make-or-break role in product formulation strategies.More here. Deep data dive report examines factors and trends driving the infant and pregnant/breastfeeding women’s probiotics category and scrutinises increasingly online-engaged consumers and their often make-or-break role in product formulation strategies.More here.
Deep data dive report examines factors and trends driving the infant and pregnant/breastfeeding women’s probiotics category and scrutinises increasingly online-engaged consumers and their often make-or-break role in product formulation strategies.
Kate Allan, British 50 Mile Time Trial Champion in 2017 and founder of endurance sports communications firm, Compete PR, developed COVID-19 symptoms back in March.
“Three weeks in, with symptoms becoming more intense, I ended up in A&E – breathless, with a horribly mucous-y cough and body aches like no other,” she wrote of her COVID-19 experience.
“…the chest x-ray showed pneumonia in my right lung and the blood tests markers of infection.”
Coming down with COVID-19 prompted her to alter her eating patterns and views of nutrition.
“I’ve started taking magnesium, vitamin D and a more general multi-vitamin, and being more mindful about taking onboard healthier foods…My skin is brighter, and although I’ve felt pretty dreadful with lurgy – I can feel that my body is functioning far more effectively than it has been.”
Full story here.
According to the International Society of Sports Nutrition (ISSN) in a lengthy position paper published at the end of 2019 in its eponymous research journal the answer is ‘yes’. But it called for more research and noted the overall research base provides only ‘modest evidence’.
What it made clear though was that the best results come from using the right strains at the right doses. ISSN said the research review that formed the basis of its position paper was complicated “by variations in clinical outcome measures and most importantly, as probiotic benefits are strain-specific, by different strains used in these studies.”
Full story here.